Lilly targets savings of $1 billion with pharma revamp and job cuts
This article was originally published in Scrip
Executive Summary
Lilly is to cut nearly 14% of its workforce and overhaul its operating structure as it begins to negotiate US healthcare reform and a wave of patent expiries. The firm will axe 5,500 jobs to outmanoeuvre "unprecedented challenges" facing the pharmaceutical industry.